UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 25

Sortiert nach

Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial

Journal of clinical oncology, 2009-12, Vol.27 (34), p.5685-5692

2009

Link zum Volltext

Verfügbarkeit prüfen

Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening

Clinical cancer research, 2008-07, Vol.14 (13), p.4103-4110

2008

Link zum Volltext

Verfügbarkeit prüfen

Risk for distant recurrence of breast cancer detected by mammography screening or other methods

JAMA : the journal of the American Medical Association, 2004-09, Vol.292 (9), p.1064

2004

Link zum Volltext

Verfügbarkeit prüfen

The Value of Sequential Serum Measurements of Gelatinases and Tissue Inhibitors During Chemotherapy in Ovarian Cancer

Anticancer research, 2006-11, Vol.26 (6C), p.4779-4784

2006

Link zum Volltext

Verfügbarkeit prüfen

High preoperative plasma TIMP‐1 is prognostic for early relapse in primary breast carcinoma

International journal of cancer, 2008-08, Vol.123 (4), p.846-851

2008

Link zum Volltext

Verfügbarkeit prüfen

High Serum TIMP-1 is Associated with Adverse Prognosis in Endometrial Carcinoma

Anticancer research, 2008-09, Vol.28 (5A), p.2715-2719

2008

Link zum Volltext

Verfügbarkeit prüfen

Increased matrix metalloproteinases 2 and 9 and tissue inhibitor of matrix metalloproteinase 2 expression is associated with progression from vulvar intraepithelial neoplasia to invasive carcinoma

Acta obstetricia et gynecologica Scandinavica, 2010-03, Vol.89 (3), p.380-384

2010

Link zum Volltext

Verfügbarkeit prüfen

Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their Tissue Inhibitors (TIMP-1 and TIMP-2) in Differential Diagnosis Between Low Malignant Potential (LMP) and Malignant Ovarian Tumours

Anticancer research, 2007-07, Vol.27 (4C), p.2753-2758

2007

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Value of Matrix Metalloproteinase-2 (MMP-2) Expression in Endometrial Endometrioid Adenocarcinoma

Anticancer research, 2005-11, Vol.25 (6B), p.4101-4105

2005

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer

The New England journal of medicine, 2006-02, Vol.354 (8), p.809-820

2006

Link zum Volltext

Verfügbarkeit prüfen

Matrix Metalloproteinase-9 (MMP-9) Immunoreactive Protein has Modest Prognostic Value in Locally Advanced Breast Carcinoma Patients Treated with an Adjuvant Antiestrogen Therapy

Anticancer research, 2004-11, Vol.24 (6), p.4247-4253

2004

Link zum Volltext

Verfügbarkeit prüfen

Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: A nationwide population-based study

Clinical cancer research, 2003-03, Vol.9 (3), p.923-930

2003

Link zum Volltext

Verfügbarkeit prüfen

Extracellular matrix interactions in early human embryos: implications for normal implantation events

Fertility and sterility, 1995-07, Vol.64 (1), p.132-138

1995

Link zum Volltext

Verfügbarkeit prüfen

Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer

Breast cancer research and treatment, 2005-02, Vol.89 (3), p.215-220

2005

Link zum Volltext

Verfügbarkeit prüfen

Matrix metalloproteinase-2 immunoreactive protein: A marker of aggressiveness in breast carcinoma

Cancer, 1998-09, Vol.83 (6), p.1153-1162

1998

Link zum Volltext

Verfügbarkeit prüfen

High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma

Breast cancer research and treatment, 2005, Vol.89 (1), p.29-34

2005

Link zum Volltext

Verfügbarkeit prüfen

Matrix metalloproteinase-2 (MMP-2) in T1-2N0 breast carcinoma

Breast cancer research and treatment, 2003, Vol.77 (1), p.85-91

2003

Link zum Volltext

Verfügbarkeit prüfen

The Absence of Immunoreactivity for Tissue Inhibitor of Metalloproteinase-1 (TIMP-1), but Not for TIMP-2, Protein Is Associated with a Favorable Prognosis in Aggressive Breast Carcinoma

Oncology, 2005-01, Vol.68 (2-3), p.196-203

2005

Link zum Volltext

Verfügbarkeit prüfen

Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy

Annals of oncology, 2007, Vol.18 (4), p.694-700

2007

Link zum Volltext

Verfügbarkeit prüfen

Front-line Bevacizumab in Serous Epithelial Ovarian Cancer: Biomarker Analysis of the FINAVAST Trial

Anticancer research, 2010-03, Vol.30 (3), p.1001-1006

2010

Link zum Volltext

Verfügbarkeit prüfen

MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma

Breast cancer research and treatment, 1999-12, Vol.58 (3), p.287-293

1999

Link zum Volltext

Verfügbarkeit prüfen

Low serum level of pro–matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma

Human pathology, 2006-10, Vol.37 (10), p.1316-1323

2006

Link zum Volltext

Verfügbarkeit prüfen

Gelatinase A-Immunoreactive Protein in Ovarian Lesions— Prognostic Value in Epithelial Ovarian Cancer

Gynecologic oncology, 1999-10, Vol.75 (1), p.91-98

1999

Link zum Volltext

Verfügbarkeit prüfen

Matrix Metalloproteinase 2 Immunoreactive Protein Appears Early in Cervical Epithelial Dedifferentiation

Gynecologic oncology, 1999-03, Vol.72 (3), p.306-311

1999

Link zum Volltext

Verfügbarkeit prüfen

Fibroblasts Stimulate Human Ovarian Cancer Cell Invasion and Expression of 72-kDa Gelatinase A (MMP-2)

Gynecologic oncology, 1997-10, Vol.67 (1), p.76-82

1997

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 25

Suche als RSS-Feed

Aktive Filter

ThemaGynecology. Andrology. Obstetrics

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial

Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening

Risk for distant recurrence of breast cancer detected by mammography screening or other methods

The Value of Sequential Serum Measurements of Gelatinases and Tissue Inhibitors During Chemotherapy in Ovarian Cancer

High preoperative plasma TIMP‐1 is prognostic for early relapse in primary breast carcinoma

High Serum TIMP-1 is Associated with Adverse Prognosis in Endometrial Carcinoma

Increased matrix metalloproteinases 2 and 9 and tissue inhibitor of matrix metalloproteinase 2 expression is associated with progression from vulvar intraepithelial neoplasia to invasive carcinoma

Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their Tissue Inhibitors (TIMP-1 and TIMP-2) in Differential Diagnosis Between Low Malignant Potential (LMP) and Malignant Ovarian Tumours

Prognostic Value of Matrix Metalloproteinase-2 (MMP-2) Expression in Endometrial Endometrioid Adenocarcinoma

Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer

Matrix Metalloproteinase-9 (MMP-9) Immunoreactive Protein has Modest Prognostic Value in Locally Advanced Breast Carcinoma Patients Treated with an Adjuvant Antiestrogen Therapy

Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: A nationwide population-based study

Extracellular matrix interactions in early human embryos: implications for normal implantation events

Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer

Matrix metalloproteinase-2 immunoreactive protein: A marker of aggressiveness in breast carcinoma

High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma

Matrix metalloproteinase-2 (MMP-2) in T1-2N0 breast carcinoma

The Absence of Immunoreactivity for Tissue Inhibitor of Metalloproteinase-1 (TIMP-1), but Not for TIMP-2, Protein Is Associated with a Favorable Prognosis in Aggressive Breast Carcinoma

Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy

Front-line Bevacizumab in Serous Epithelial Ovarian Cancer: Biomarker Analysis of the FINAVAST Trial

MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma

Low serum level of pro–matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma

Gelatinase A-Immunoreactive Protein in Ovarian Lesions— Prognostic Value in Epithelial Ovarian Cancer

Matrix Metalloproteinase 2 Immunoreactive Protein Appears Early in Cervical Epithelial Dedifferentiation

Fibroblasts Stimulate Human Ovarian Cancer Cell Invasion and Expression of 72-kDa Gelatinase A (MMP-2)

Aktive Filter

Suchergebnisse filtern